Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma
暂无分享,去创建一个
G. Waris | O. Cevik | Neerja Kaushik-Basu | B. Barnes | E. Pimenta | Dan Li | E. Baljinnyam | Dinesh Manvar
[1] V. Paradis,et al. IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans. , 2016, JCI insight.
[2] B. Barnes,et al. Specific detection of interferon regulatory factor 5 (IRF5): A case of antibody inequality , 2016, Scientific Reports.
[3] D. V. van Thiel,et al. Hepatitis C virus: A time for decisions. Who should be treated and when? , 2016, World journal of gastrointestinal pharmacology and therapeutics.
[4] R. Hartmann,et al. Guarding the frontiers: the biology of type III interferons , 2015, Nature Immunology.
[5] G. Bhanot,et al. IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5+ B‐ and T‐cell trafficking to tumor‐conditioned media , 2015, Immunology and cell biology.
[6] H. Barth. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. , 2015, World journal of hepatology.
[7] B. Barnes,et al. A conserved region within interferon regulatory factor 5 controls breast cancer cell migration through a cytoplasmic and transcription-independent mechanism , 2015, Molecular Cancer.
[8] Hongliang Li,et al. Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. , 2015, Biochimica et biophysica acta.
[9] F. Ciccosanti,et al. Autophagy in HCV Infection: Keeping Fat and Inflammation at Bay , 2014, BioMed research international.
[10] Daniel G. Anderson,et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. , 2013, Journal of the American College of Cardiology.
[11] H. Hauser,et al. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms. , 2013, Gastroenterology.
[12] Neerja Kaushik-Basu,et al. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase. , 2013, European journal of medicinal chemistry.
[13] G. Dore,et al. Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.
[14] A. Paradiso,et al. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma , 2013, Journal of experimental & clinical cancer research : CR.
[15] A. Flaxman,et al. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.
[16] B. Bartosch,et al. Hepatitis C Virus-Induced Mitochondrial Dysfunctions , 2013, Viruses.
[17] H. M. Reis,et al. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma , 2013, Nature Reviews Cancer.
[18] G. Bhagat,et al. Akt-Mediated Regulation of Autophagy and Tumorigenesis Through Beclin 1 Phosphorylation , 2012, Science.
[19] A. Bishayee,et al. Angiogenesis in hepatocellular carcinoma: a potential target for chemoprevention and therapy. , 2012, Current cancer drug targets.
[20] J. Martinez-Climent,et al. High‐throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal‐zone lymphoma , 2012, British journal of haematology.
[21] K. Meyer,et al. Hepatitis C Virus-Mediated Inhibition of Cathepsin S Increases Invariant-Chain Expression on Hepatocyte Surface , 2012, Journal of Virology.
[22] R. Ray,et al. Hepatitis C Virus Upregulates Beclin1 for Induction of Autophagy and Activates mTOR Signaling , 2012, Journal of Virology.
[23] M. Hameed,et al. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis , 2011, Breast Cancer Research.
[24] Jian Yu,et al. Cleaving Beclin 1 to suppress autophagy in chemotherapy-induced apoptosis , 2011, Autophagy.
[25] T. Asselah,et al. Changes in autophagic response in patients with chronic hepatitis C virus infection. , 2011, The American journal of pathology.
[26] R. Ray,et al. Knockdown of autophagy enhances the innate immune response in hepatitis C virus–infected hepatocytes , 2011, Hepatology.
[27] R. Ray,et al. Hepatitis C Virus Infection Impairs IRF-7 Translocation and Alpha Interferon Synthesis in Immortalized Human Hepatocytes , 2010, Journal of Virology.
[28] Wei-Guo Zhu,et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity , 2010, Nature Cell Biology.
[29] Hyun Kook Cho,et al. Curcumin inhibits hepatitis C virus replication via suppressing the Akt‐SREBP‐1 pathway , 2010, FEBS letters.
[30] K. Kersse,et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria , 2010, Cell Death and Disease.
[31] D. Rubinsztein,et al. Apoptosis blocks Beclin 1-dependent autophagosome synthesis – an effect rescued by Bcl-xL , 2009, Cell Death and Differentiation.
[32] F. Chisari,et al. The autophagy machinery is required to initiate hepatitis C virus replication , 2009, Proceedings of the National Academy of Sciences.
[33] T. Taniguchi,et al. A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis , 2008, Proceedings of the National Academy of Sciences.
[34] M. Binder,et al. Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy , 2007, Hepatology.
[35] K. Honda,et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression , 2007, Proceedings of the National Academy of Sciences.
[36] Colin W Shepard,et al. Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.
[37] B. Barnes,et al. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. , 2005, Cancer research.
[38] Toshiaki Maruyama,et al. Complete Replication of Hepatitis C Virus in Cell Culture , 2005, Science.
[39] Katherine E. M. Hoops,et al. Two Discrete Promoters Regulate the Alternatively Spliced Human Interferon Regulatory Factor-5 Isoforms , 2005, Journal of Biological Chemistry.
[40] D. Golenbock,et al. The Interferon Regulatory Factor, IRF5, Is a Central Mediator of Toll-like Receptor 7 Signaling* , 2005, Journal of Biological Chemistry.
[41] Tak W. Mak,et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors , 2005, Nature.
[42] T. Ohshima,et al. Suppression of hepatitis C virus replicon by TGF-beta. , 2005, Virology.
[43] P. Pitha,et al. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. , 2003, Cancer research.
[44] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[45] D. Rowlands,et al. Viral Internal Ribosome Entry Site Structures Segregate into Two Distinct Morphologies , 2003, Journal of Virology.
[46] Stanley M. Lemon,et al. Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease , 2003, Science.
[47] R. Ray,et al. Modulation of interferon expression by hepatitis C virus NS5A protein and human homeodomain protein PTX1. , 2003, Virology.
[48] Charles M. Rice,et al. Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication , 2002, Journal of Virology.
[49] P. Pitha,et al. Multiple Regulatory Domains of IRF-5 Control Activation, Cellular Localization, and Induction of Chemokines That Mediate Recruitment of T Lymphocytes , 2002, Molecular and Cellular Biology.
[50] Yusuke Nakamura,et al. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53 , 2002, Oncogene.
[51] M. Gale,et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[52] P. Moore,et al. Virus-specific Activation of a Novel Interferon Regulatory Factor, IRF-5, Results in the Induction of Distinct Interferon α Genes* , 2001, The Journal of Biological Chemistry.
[53] T. Taniguchi,et al. The IRF family transcription factors at the interface of innate and adaptive immune responses. , 2013, Cold Spring Harbor symposia on quantitative biology.
[54] O. Kemik,et al. Circulating levels of VEGF family and their receptors in hepatocellular carcinoma. , 2010, Bratislavske lekarske listy.
[55] S. Kaufmann,et al. Chemotherapy-induced apoptosis. , 1997, Advances in pharmacology.